{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-122485","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.948561+00:00","generated_at":"2026-05-21T01:19:19.224483+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"Lyra Therapeutics approves 1-for-50 reverse stock split, effective May 27","bullets":["Stockholders approved reverse-split authority at 1-for-10 to 1-for-50 range; Board set final ratio at 1-for-50.","Reverse split effective 5:00 p.m. ET May 27, 2025; split-adjusted trading starts May 28 under symbol LYRA.","No fractional shares issued; holders receive cash payment based on May 27 closing price.","CUSIP changes to 55234L204 after split."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-122485","json":"https://secwatch.observer/filing/0001193125-25-122485.json","markdown":"https://secwatch.observer/filing/0001193125-25-122485.md","text":"https://secwatch.observer/filing/0001193125-25-122485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525122485/0001193125-25-122485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525122485/d932010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:19:19.224483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}